Abstract
The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sawyers, C. L. Genes Dev. 17, 2998–3010 (2002).
Paez, J. G. et al. Science 304, 1497–1500 (2004).
Lynch, T. J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).
Futreal, P. A. et al. Nature Rev. Cancer 4, 177–183 (2004).
Slamon, D. J. et al. Science 235, 177–182 (1987).
Klapper, S. et al. Adv. Cancer Res. 1, 25–79 (2000).
Hirsch, F. R. & Langer, C. J. Semin. Oncol. 31, 75–82 (2004).
Rosell, R. J. Clin. Oncol. 22, 1171–1173 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Stephens, P., Hunter, C., Bignell, G. et al. Intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004). https://doi.org/10.1038/431525b
Published:
Issue Date:
DOI: https://doi.org/10.1038/431525b
This article is cited by
-
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
Cancer Immunology, Immunotherapy (2022)
-
Other signalization targets
Targeted Oncology (2013)
-
NF-κB addiction and its role in cancer: ‘one size does not fit all’
Oncogene (2011)
-
Expression of NRG1 and its receptors in human bladder cancer
British Journal of Cancer (2011)
-
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
Oncogene (2010)